This HTML5 document contains 39 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/drugbank/drug/DB05465/identifier/drugbank/
n6http://bio2rdf.org/drugbank:
n11http://linked.opendata.cz/resource/drugbank/drug/DB05465/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/resource/drugbank/drug/DB05465/identifier/bindingdb/
n9http://linked.opendata.cz/resource/drugbank/drug/DB05465/identifier/pubchem-compound/

Statements

Subject Item
n2:DB05465
rdf:type
n3:Drug
n3:description
MLN518 is a novel, oral, small molecule designed to inhibit type III receptor tyrosine kinases, including FLT3, (platelet-derived growth-factor receptor) PDGFR and c-KIT. Tyrosine kinases are enzymes involved in several cellular processes and are known to be activated in cancer cells to drive tumor growth. AML patients with FLT3 mutations experience earlier disease relapse and shorter survival rates compared to patients without these mutations. Approximately 25 to 30 percent of all adult AML patients have a mutation of the FLT3 gene. The use of MLN518 to treat AML has been granted fast-track status by the U.S. Food and Drug Administration. Phase I/II trials are underway.
n3:generalReferences
# DeAngelo DJ, Stone RM, Heaney ML, Nimer SD, Paquette RL, Klisovic RB, Caligiuri MA, Cooper MR, Lecerf JM, Karol MD, Sheng S, Holford N, Curtin PT, Druker BJ, Heinrich MC: Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood. 2006 Dec 1;108(12):3674-81. Epub 2006 Aug 10. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16902153 # Kiyoi H: [The present status of, and problems with the development of FLT3 kinase inhibitors] Rinsho Ketsueki. 2006 Apr;47(4):270-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16715961 # Kiyoi H: [Possibility of targeting FLT3 kinase for the treatment of leukemia] Rinsho Ketsueki. 2005 Mar;46(3):187-97. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16447713 # Griswold IJ, Shen LJ, La Rosee P, Demehri S, Heinrich MC, Braziel RM, McGreevey L, Haley AD, Giese N, Druker BJ, Deininger MW: Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis. Blood. 2004 Nov 1;104(9):2912-8. Epub 2004 Jul 8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15242881 # Brownlow N, Vaid M, Dibb NJ: Tandutinib inhibits FMS receptor signalling, and macrophage and osteoclast formation in vitro. Leukemia. 2008 Jan 10;. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18185521
n3:group
investigational
n3:indication
Investigated for use/treatment in leukemia (myeloid).
owl:sameAs
n6:DB05465
dcterms:title
MLN-518
adms:identifier
n8:DB05465 n9:3038522 n10:13535 n11:2302085
n3:mechanismOfAction
MLN518 inhibits tyrosine kinases; Specifically, it is selective for FLT3, KIT, and platelet-derived growth-factor receptor (PDGFR).
n3:synonym
tandutinib
n3:IUPAC-Name
n4:271B4491-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4497-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4496-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4493-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4494-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4495-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B448F-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B448D-363D-11E5-9242-09173F13E4C5 n4:271B4490-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B448E-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B449D-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B449E-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4498-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4499-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B449B-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B449A-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B449C-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B44A3-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B44A5-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B44A6-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B44A2-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B44A1-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B44A4-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4492-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B449F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B44A0-363D-11E5-9242-09173F13E4C5